KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Total Non-Current Liabilities: 2009-2025

Historic Total Non-Current Liabilities for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Sep 2025 value amounting to $1.4 billion.

  • Biomarin Pharmaceutical's Total Non-Current Liabilities rose 6.47% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 6.47%. This contributed to the annual value of $1.2 billion for FY2024, which is 32.09% down from last year.
  • According to the latest figures from Q3 2025, Biomarin Pharmaceutical's Total Non-Current Liabilities is $1.4 billion, which was up 8.96% from $1.3 billion recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Total Non-Current Liabilities peaked at $1.8 billion during Q4 2023, and registered a low of $1.2 billion during Q4 2024.
  • For the 3-year period, Biomarin Pharmaceutical's Total Non-Current Liabilities averaged around $1.5 billion, with its median value being $1.7 billion (2024).
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Total Non-Current Liabilities rose by 13.08% in 2021, and later crashed by 32.09% in 2024.
  • Biomarin Pharmaceutical's Total Non-Current Liabilities (Quarterly) stood at $1.6 billion in 2021, then climbed by 1.90% to $1.7 billion in 2022, then grew by 5.87% to $1.8 billion in 2023, then crashed by 32.09% to $1.2 billion in 2024, then rose by 6.47% to $1.4 billion in 2025.
  • Its last three reported values are $1.4 billion in Q3 2025, $1.3 billion for Q2 2025, and $1.2 billion during Q1 2025.